BIO BIO-RAD LABORATORIES, INC.
Laboratory Analytical Instruments · NYSE · SEC CIK 12208 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.4%
TTM net income YoY251.3%
TTM EPS YoY254.8%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR—
Margins
Gross margin51.3%
Operating margin-2.4%
Net margin39.5%
FCF margin12.7%
EBITDA margin—
Returns
ROE14.3%
ROA10.0%
ROIC (approx.)-0.6%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets29.5%
Debt / equity0.11x
Current ratio3.18x
Interest coverage-1.27x
Cash quality & payout
Operating cash flow / net income0.46x
Accruals ratio5.4%
Payout ratio—
Capex / revenue5.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $656.40M | $651.00M | $592.10M | $693.20M | $653.00M | $651.60M | $585.40M | $667.50M |
| Cost of revenue | $327.80M | $305.20M | $282.70M | $348.00M | $309.60M | $306.30M | $279.40M | $325.56M |
| Gross profit | $328.60M | $345.80M | $309.40M | $345.20M | $343.40M | $345.30M | $306.00M | $342.00M |
| R&D expense | $71.40M | $61.20M | $62.90M | $70.30M | $71.30M | $60.50M | $73.50M | $79.62M |
| SG&A expense | $257.10M | $212.00M | $212.40M | $221.00M | $206.80M | $207.70M | $208.80M | $203.96M |
| Operating income | -$49.70M | $72.60M | $34.10M | -$118.90M | $65.30M | $77.10M | $23.70M | $58.33M |
| Interest expense | $12.30M | $12.10M | $12.30M | $12.10M | $12.30M | $12.60M | $12.00M | $12.19M |
| Pretax income | $538.70M | $542.10M | -$689.80M | $929.20M | -$431.10M | $414.00M | $83.40M | -$908.90M |
| Income tax | $80.10M | $170.70M | -$162.70M | $209.20M | -$89.20M | $96.20M | $19.40M | -$193.12M |
| Net income | $458.60M | $371.40M | -$527.10M | $720.00M | -$341.90M | $317.80M | $64.00M | -$715.80M |
| EPS (basic) | 17.13 | 13.89 | -19.55 | — | -12.70 | 11.67 | 2.29 | -25.57 |
| EPS (diluted) | 17.02 | 13.85 | -19.55 | — | -12.70 | 11.67 | 2.29 | -25.57 |
| Weighted avg. shares (diluted) | 26.95M | 26.81M | 26.96M | — | 26.92M | 27.23M | 27.95M | — |
| Banking | ||||||||
| Provision for credit losses | — | — | — | $0 | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $465.30M | $517.00M | $507.20M | $529.80M | $395.80M | $369.30M | $521.40M | $489.80M |
| Short-term investments | $1.20B | $1.10B | $1.06B | $1.01B | $1.02B | $1.00B | $1.14B | $1.18B |
| Receivables | $422.60M | $441.80M | $426.20M | $460.60M | $464.70M | $469.90M | $424.70M | $452.50M |
| Inventory | $783.90M | $780.60M | $770.50M | $740.70M | $783.20M | $798.80M | $790.10M | $760.00M |
| Current assets | $3.08B | $3.02B | $2.94B | $2.91B | $2.84B | $2.81B | $3.04B | $3.03B |
| PP&E, net | $505.70M | $517.90M | $527.50M | $539.90M | $540.20M | $549.70M | $528.50M | $528.10M |
| Goodwill | $573.00M | $574.30M | $577.10M | $579.80M | $578.70M | $581.60M | $414.60M | $410.50M |
| Intangibles | $104.40M | $160.00M | $166.80M | $174.30M | $388.40M | $396.90M | $296.10M | $293.60M |
| Total assets | $10.78B | $10.25B | $9.79B | $10.58B | $9.70B | $10.21B | $9.53B | $9.36B |
| Current liabilities | $969.10M | $961.30M | $917.00M | $517.00M | $522.30M | $548.90M | $506.60M | $467.80M |
| Long-term debt | $803.10M | $803.00M | $802.90M | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B |
| Total debt | $803.10M | $803.00M | $802.90M | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B |
| Total liabilities | $3.18B | $3.08B | $2.94B | $3.12B | $2.96B | $3.09B | $2.85B | $2.79B |
| Shareholders' equity | $7.60B | $7.17B | $6.85B | $7.45B | $6.74B | $7.13B | $6.68B | $6.57B |
| Net debt | $337.80M | $286.00M | $295.70M | $671.90M | $805.60M | $831.80M | $679.30M | $710.60M |
| Cash flow statement | ||||||||
| Operating cash flow | $96.40M | $98.70M | $108.10M | $164.90M | $120.90M | $116.50M | $129.90M | $124.15M |
| Capital expenditure | $31.20M | $32.00M | $30.00M | $45.80M | $31.70M | $45.70M | $34.40M | $42.91M |
| Free cash flow | $65.20M | $66.70M | $78.10M | $119.10M | $89.20M | $70.80M | $95.50M | $81.24M |
| Investing cash flow | -$145.90M | -$66.70M | -$93.20M | -$34.20M | -$43.00M | -$115.40M | $2.90M | -$30.54M |
| Financing cash flow | -$1.60M | -$27.60M | -$44.00M | $3.30M | -$52.50M | -$136.30M | -$97.70M | -$26.25M |
| Stock-based compensation | $15.50M | $14.50M | $15.00M | $15.90M | $14.90M | $11.90M | $15.30M | $16.40M |
| Share buybacks | $0 | $31.50M | $47.80M | $0 | $53.40M | $140.20M | $101.90M | $14,000 |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.